377 related articles for article (PubMed ID: 35130342)
21. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
22. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
23. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
[TBL] [Abstract][Full Text] [Related]
24. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
25. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract][Full Text] [Related]
26. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
27. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK
Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
29. Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.
Kamitani I; Saito T; Yokoyama H; Nakano A; Ishii H; Tanoue S; Hattori D; Oshima S; Ishii S; Gunji T; Fukushima R; Katsube A; Shimada T; Nishiwaki K; Dobashi N; Yano S
J Infect Chemother; 2021 Apr; 27(4):639-641. PubMed ID: 33214069
[TBL] [Abstract][Full Text] [Related]
30. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.
Wang X; DeFilippis RA; Weldemichael T; Gunaganti N; Tran P; Leung YK; Shah NP; Li HY
Eur J Med Chem; 2024 Jan; 264():115977. PubMed ID: 38056299
[TBL] [Abstract][Full Text] [Related]
31. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
32. Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
Kang C; Blair HA
Target Oncol; 2020 Oct; 15(5):681-689. PubMed ID: 32940858
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
34. RNA-based
Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
[TBL] [Abstract][Full Text] [Related]
35. Gilteritinib: First Global Approval.
Dhillon S
Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452
[TBL] [Abstract][Full Text] [Related]
36. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C
Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax Plus Gilteritinib for
Daver N; Perl AE; Maly J; Levis M; Ritchie E; Litzow M; McCloskey J; Smith CC; Schiller G; Bradley T; Tiu RV; Naqvi K; Dail M; Brackman D; Siddani S; Wang J; Chyla B; Lee P; Altman JK
J Clin Oncol; 2022 Dec; 40(35):4048-4059. PubMed ID: 35849791
[TBL] [Abstract][Full Text] [Related]
38. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
[TBL] [Abstract][Full Text] [Related]
39. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X
Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204
[TBL] [Abstract][Full Text] [Related]
40. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
